60 avenue Rockefeller
Full-time employees: 18
|Mr. Franck Mouthon||Chairman & CEO||280.98k||N/A||N/A|
|Mr. Mathieu CharvÃ©riat||Chief Scientific Officer, Deputy CEO & Director||240.48k||N/A||N/A|
|Mr. Thierry Lambert||CFO and Admin. & Financial director||N/A||N/A||1954|
|Mr. Julien Veys||Chief Bus. Devel. Officer||N/A||N/A||N/A|
|Mr. Werner Rein||Chief Medical Officer||N/A||N/A||N/A|
Theranexus sociÃ©tÃ© anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.
Theranexus Société Anonyme’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.